| Download | - View final version: Development of lipid nanoparticles and liposomes reference materials (II): cytotoxic profiles (PDF, 2.2 MiB)
- View supplementary information: Development of lipid nanoparticles and liposomes reference materials (II): cytotoxic profiles (PDF, 191 KiB)
|
|---|
| DOI | Resolve DOI: https://doi.org/10.1038/s41598-022-23013-2 |
|---|
| Author | Search for: Syama, Krishnapriya1; Search for: Jakubek, Zygmunt J.1ORCID identifier: https://orcid.org/0000-0003-3307-8464; Search for: Chen, Sam; Search for: Zaifman, Josh; Search for: Tam, Yuen Yi C.; Search for: Zou, Shan1ORCID identifier: https://orcid.org/0000-0002-2480-6821 |
|---|
| Affiliation | - National Research Council of Canada. Metrology Research Centre
|
|---|
| Format | Text, Article |
|---|
| Subject | drug development; nanoscale materials |
|---|
| Abstract | Lipid based nanocarriers are one of the most effective drug delivery systems that is evident from the recent COVID-19 mRNA vaccines. The main objective of this study was to evaluate toxicity of six lipid based formulations with three surface charges—anionic, neutral or cationic, to establish certified reference materials (CRMs) for liposomes and siRNA loaded lipid nanoparticles (LNP-siRNA). Cytotoxicity was assessed by a proliferation assay in adherent and non-adherent cell lines. High concentration of three LNP-siRNAs did not affect viability of suspension cells and LNP-siRNAs were non-toxic to adherent cells at conventionally used concentration. Systematic evaluation using multiple vials and repeated test runs of three liposomes and three LNP-siRNA formulations showed no toxicity in HL60 and A549 cells up to 128 and 16 µg/mL, respectively. Extended treatment and low concentration of LNPs did not affect the viability of suspension cells and adherent cells at 96 h. Interestingly, 80% of A549 and HL60 cells in 3D conditions were viable when treated with cationic LNP-siRNA for 48 h. Taken together, anionic, cationic and neutral lipid formulations were non-toxic to cells and may be explored further in order to develop them as drug carriers. |
|---|
| Publication date | 2022-10-27 |
|---|
| Publisher | Springer Nature |
|---|
| Licence | |
|---|
| In | |
|---|
| Language | English |
|---|
| Peer reviewed | Yes |
|---|
| Export citation | Export as RIS |
|---|
| Report a correction | Report a correction (opens in a new tab) |
|---|
| Record identifier | cfb9ec4b-a14a-4e7d-81dd-84eff267d37d |
|---|
| Record created | 2023-01-09 |
|---|
| Record modified | 2023-01-09 |
|---|
